Drugs / JNJ-87562761
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06604715 | Dec 2024 → Nov 2027 expected | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-87562761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604715 ↗ |